Indranil Chatterjee1* and Manas Chakraborty2*
1Assistant Professor, Department of Microbiology, Birbhum Pharmacy School,
Birbhum, West Bengal, India
2Professor, Department of Pharmaceutical Biotechnology, Calcutta Institute of
Pharmaceutical Technology and Allied Health Sciences, Howrah, West Bengal, India
*Corresponding Author: Indranil Chatterjee, Assistant Professor, Department of Microbiology, Birbhum Pharmacy School, Birbhum, West Bengal, India and Manas Chakraborty Professor, Department of Pharmaceutical Biotechnology, Calcutta Institute of Pharmaceutical Technology and Allied Health Sciences, Howrah, West Bengal, India.
Received: March 30, 2020; Published: April 14, 2020
A movement to reposition tablets has been initiated in current years [1]. In this strategy, it is vital to use tablets which have been tested to be harmless and whose pharmacokinetics and most advantageous dosage are well known. In the current episode of novel coronavirus (SARS-CoV-2) emergence [2], we find a wonderful ex- enough of possible repositioning of tablets, especially chloroquine. We had 20 years ago proposed to systematically check chloroquine in viral infections as it have been proven to be powerful in vitro against a broad variety of viruses [3,4]. This drug has more than one activity, one among that's to alkalise the phagolysosome, which hampers the low-pH-based steps of viral replication, along with fusion and uncoating [4]. Other mechanisms of antiviral hobby are poorly explained [5].
Citation: Indranil Chatterjee and Manas Chakraborty. “Chloroquine as Reposition Drugs for Novel Coronavirus SARS-COV-2 Emergence" Acta Scientific Microbiology 3.5 (2020): 37-38.
Copyright: © 2020 Indranil Chatterjee and Manas Chakraborty. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.